Revelation Biosciences, Inc. Releases Corporate Update Letter to Stockholders

About this update from Revelation Biosciences, Inc.

[{"type":"text","content":"SAN DIEGO, CA / ACCESS Newswire / May 11, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company developing innovative solutions to treat acute and chronic disease, released its 2026 annual meeting proxy materials today, which included a corporate update letter to its stockholders from James Rolke, Chief Executive Officer of Revelation, the body of the letter follows.","length":457,"tagName":"p"},{"type":"text","content":"Dear Stockholders:","length":18,"tagName":"p"},{"type":"text","content":"As you know, Revelation is a clinical stage company working to develop a high-impact, potentially lifesaving drug called Gemini for the treatment of acute kidney injury (AKI). While our passionate team is dedicated and hardworking, we couldn't accomplish anything without the financial support of our investors and stockholders and, to this end, the team and I are truly grateful. We take very seriously our obligation to deliver on and exceed our stated objectives while being very mindful of - and maximizing the value of - every dollar spent.","length":549,"tagName":"p"},{"type":"text","content":"I'm a firm believer in open, honest and transparent communication. As a stockholder myself, I believe our stock is significantly undervalued given our current phase of development, the strong data supporting our mechanism of action, the potential addressable AKI market and the potential of Gemini for the treatment of other acute and chronic diseases. Thus the purpose of this letter is to reflect on the significance of these points and to discuss the future planned development of Gemini for the benefit of patients and, ultimately, the stockholder value it is expected to create.","length":587,"tagName":"p"},{"type":"text","content":"Current Phase of Development","length":28,"tagName":"p"},{"type":"text","content":"In December 2025 we had a very productive and successful meeting with the FDA regarding the approval pathway for Gemini as a treatment for AKI. The key agreements were:","length":168,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"A clinically relevant and objective composite endpoint comprising death and/or dialysis; and","length":92,"tagName":"p"}]},{"val":[{"type":"text","content":"Positive data from a single well-control...

More updates from Revelation Biosciences, Inc.